MedTrace Logo

Prognostic Value of PD-L1 in NSCLC

NCT03078959 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2017-03-14

No results posted yet for this study

Summary

This is an observational retrospective study. The primary objective is to investigate the expression and potential prognostic role of Programmed Death Ligand 1 (PD-L1) in tumor samples from 350 patients with early stage treatment-naive non-small-cell lung cancer (NSCLC).

Tissue samples were embedded in a tissue microarray. PD-L1 will be studied by immunohistochemistry using the SP263 antibody. Stained samples will be evaluated independently by two operators. A tumor will be defined as positive when = or \>50% of tumor cells express the ligand.

The investigators will investigate the relationship between PD-L1 protein expression and overall survival and other clinical characteristics with appropriate statistical methods.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

OTHER

immunohistochemistry

Samples will be stained using the SP263 antibody clone against PD-L1

Sponsors & Collaborators

  • Fondazione Ricerca Traslazionale

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-03
Primary Completion
2017-03-30
Completion
2017-04-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03078959 on ClinicalTrials.gov